This inventor holds 1 USPTO granted patent. Top assignee: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. . Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: The Innovations of Hans Mollenkopf
Introduction
Hans Mollenkopf is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of immunology through his innovative research and patents. His work focuses on the identification of specific differentially expressed antigens, which has important implications for vaccine development and diagnostics.
Latest Patents
Mollenkopf holds a patent titled "Identification of specific differentially expressed antigens." This invention relates to compositions useful in immunization against pathogenic organisms and for diagnostic purposes. The patent describes a composition comprising at least one protein that is differentially expressed in a virulent strain compared to an avirulent strain. Additionally, it includes fusion proteins, antigenic fragments, nucleic acid molecules encoding the aforementioned proteinaceous compounds, and antibodies. The invention also covers pharmaceutical and diagnostic compositions that utilize these compounds for treating induced diseases and preparing vaccines.
Career Highlights
Hans Mollenkopf is affiliated with the Max Planck Society for the Advancement of Science, a prestigious research institution known for its cutting-edge scientific research. His work has contributed to advancements in immunology and has the potential to impact public health positively.
Collaborations
Mollenkopf has collaborated with esteemed colleagues such as Ulrich E. Schaible and Bärbel Raupach. These collaborations have further enriched his research and have led to significant findings in the field.
Conclusion
Hans Mollenkopf's innovative work in identifying differentially expressed antigens showcases his commitment to advancing immunological research. His contributions have the potential to lead to significant breakthroughs in vaccine development and diagnostics.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
